Apellis Pharmaceuticals, Inc. 4

Director Paul R. Fonteyne’s 30,666 Apellis common shares and all outstanding options were cancelled or cashed out for $41.00 per share plus contingent value rights (or, for higher‑strike options, for no consideration) in connection with Biogen’s acquisition of Apellis.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., reporting person Paul R. Fonteyne had all of his Apellis equity interests effectively cashed out or cancelled pursuant to the merger agreement. A total of 30,666 shares of Apellis common stock previously reported as beneficially owned were exchanged in the tender offer/merger for $41.00 in cash per share plus one contingent value right (CVR) per share, with no post‑closing share ownership remaining. In addition, several blocks of common stock associated with prior RSU or similar awards (3,062; 5,744; 7,961; 3,544; and 3,877 shares) were similarly terminated and converted into the right to receive cash at $41.00 per share plus CVRs, subject to applicable vesting conditions in the case of converted RSUs. Separately, multiple stock option grants were cancelled: vested or transaction‑vested “in‑the‑money” options with exercise prices below $41.00 (25.12, 26.13, 31.91) were transformed into cash payments equal to the intrinsic value per share (the $41.00 cash amount minus the strike price) plus one CVR per underlying share, while underwater or minimally in‑the‑money options at higher exercise prices (47.28, 51.71, 57.20, 59.86) were cancelled without consideration in accordance with the merger terms. After these transactions, Fonteyne no longer held any Apellis common stock or options, and Apellis became a wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224618

Alert Tier

6